Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of tirabrutinib + entospletinib with or without obinutuzumab in relapsed or refractory chronic lymphocytic leukemia
2016-002768-15Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tirabrutinib, entospletinib and obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Complete remission rate at Week 25. Started Sep 2016; status: completed.
02
Drugs
tirabrutinibentospletinibobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2016-002768-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002768-15.